ATXN2 and amyotrophic lateral sclerosis: Interestingly, the ASO BIIB105 has been designed against polyQ-ATXN2 for the treatment of ALS subjects carrying an ATXN2 intermediate allele (30-33 CAG/CAA repeats) [172].